Pernix Therapeutics has selected compliance blister packaging for its ten-day, triple combination oral therapy for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease. Comprising omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg), and amoxicillin capsules (500 mg), the Omeclamox-Pak is the first triple combination medication indicated to eradicate symptoms of H. pylori in just ten days now available to patients, the company reports. Other treatments take up to 14 days.
“There is a lot of pain and discomfort with this condition,” explains Joe Schepers, director of investor relations for Pernix. “In most cases, patients can resolve the situation with therapy. But patients must continue the regimen to get the full benefits.”
Pernix cites Dr. Brian Fennerty, M.D., Professor of Medicine, Division of Gastroenterology at Oregon Health & Science University, who has been quoted in a press release as saying: “Published studies show that a single ten-day regimen of twice-daily therapy with omeprazole, amoxicillin and clarithromycin eradicates 80 percent to 90 percent of H. pylori infections.”
Pernix opted for compliance packaging. “Any time you can take medication for a shorter length of time, compliance is encouraged,” Schepers adds. However, the company wanted to ease the twice-daily multiple-dose regimen as much as possible and selected compliance packaging.
“We wanted to offer a simple-to-follow therapy and encourage compliance,” says Schepers. “Our product includes three different prescription drugs, each taken twice daily. We knew we had to help patients with compliance.”
One day’s morning and evening doses—consisting of four tablets each—make up one blister card. Blister lidding is printed so that dosing and instructions show through the blister film. Ten blister cards are provided in a color-coordinated carton. “Patients know exactly that they are following the regimen with this packaging,” he says. The colors duplicate those found throughout all on-line marketing and other materials, even those of a $100-off coupon found on-line, encouraging product recognition throughout the healthcare supply chain.
Schepers says that Omeclamox-Pak “seems to be well received” by both doctors and pharmacists. “It is a simpler process to explain to the patient, and it takes less time to dispense. It also takes up less space on the shelf than competing products.”
Omeclamox-Pak was approved by the U.S. FDA in 2011.